Cart
sales@molnova.com
Zavondemstat
CAS No. 1851412-93-5
Zavondemstat( —— )
Catalog No. M36329 CAS No. 1851412-93-5
Zavondemstat (QC8222 free base) is a histone lysine demethylase 4 (KDM4) inhibitor with anticancer and antitumor activity for the study of triple-negative and breast cancers.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 231 | Get Quote |
|
| 5MG | 359 | Get Quote |
|
| 10MG | 588 | Get Quote |
|
| 25MG | 1132 | Get Quote |
|
| 50MG | 1822 | Get Quote |
|
| 100MG | 2250 | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameZavondemstat
-
NoteResearch use only, not for human use.
-
Brief DescriptionZavondemstat (QC8222 free base) is a histone lysine demethylase 4 (KDM4) inhibitor with anticancer and antitumor activity for the study of triple-negative and breast cancers.
-
DescriptionZavondemstat (QC8222; TACH 101) is an inhibitor of histone lysine demethylase 4D (KDM4D) with antineoplastic activity.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayChromatin/Epigenetic
-
TargetHistone Demethylase
-
RecptorHistone Demethylase
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1851412-93-5
-
Formula Weight431.53
-
Molecular FormulaC26H29N3O3
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESC(NC=1C(C(O)=O)=CC=NC1)[C@H]2C=3C(=CC(N(C)C4=CC=C(C(C)C)C=C4)=CC3)OCC2
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. WHO Drug Information-World Health Organization (WHO).
molnova catalog
related products
-
KDM5-C70
KDM5-C70 is the cell-permeable derivative of KDM5-C49, potent, selective and cell permeable KDM5 inhibitor with IC50 of 0.3, 0.3 and 0.58 uM for KDM5A, B and C, respectively.
-
KDM5A covalent inhib...
KDM5A covalent inhibitor N71 is an irreversible KDM5A inhibitor (IC50=0.22 uM) that covalently interacts with Cys481.
-
Zavondemstat
Zavondemstat (QC8222 free base) is a histone lysine demethylase 4 (KDM4) inhibitor with anticancer and antitumor activity for the study of triple-negative and breast cancers.
